AbbVie Partners With Boehringer To Take On Stelara In Psoriasis
This article was originally published in The Pink Sheet Daily
Phase III anti-IL-23 candidate BI 655066 bested Stelara for several measures of efficacy in a Phase II head-to-head study. AbbVie is paying $595m up front for rights to the antibody.
Register for our free email digests: